Performance evaluation of CA242 by flow fluorescence assay.
Yanyan Hou1, Yongquan Chen, Jieli Sun
1Xiamen Key Laboratory of Biomarker Translational Medicine, Center of Clinical Laboratory, Xiamen Humanity Hospital Fujian Medical University, Xiamen, Fujian, China.
Medicine
|April 13, 2021
Summary
A new quantitative assay kit for Carbohydrate Antigen 24-2 (CA24-2) demonstrates excellent performance for pancreatic and colorectal cancer diagnosis. This assay shows high accuracy, precision, and consistency with existing methods, making it suitable for clinical use.
Area of Science:
- Clinical chemistry
- Immunoassay development
- Cancer biomarker detection
Background:
- Carbohydrate antigen 24-2 (CA24-2) is a recognized biomarker for pancreatic and colorectal cancers.
- Existing diagnostic methods for CA24-2 require evaluation for new assay kits.
- Accurate and reliable CA24-2 quantification is crucial for effective cancer diagnosis and monitoring.
Purpose of the Study:
- To evaluate the performance of a newly developed quantitative assay kit for CA24-2 using flow fluorometry assay (FFA).
- To assess the accuracy, precision, linearity, and reportable range of the new CA24-2 assay kit.
- To compare the new assay kit with an established method and evaluate its suitability for clinical application.
Main Methods:
- Performance evaluation of the new CA24-2 assay kit according to established guidelines (Guiding principles on performance analysis of diagnostic reagents in vitro, EP15-A2).
- Assessment of accuracy, precision, linear and reportable ranges, biological reference interval, carry-over contamination, anti-interference, and cross-reactivity.
- Parallel analysis with the CanAg kit to determine correlation and consistency.
Main Results:
- The new CA24-2 assay kit exhibited accuracy bias <12.5% and precision CVs <10.0%.
- Linear range was 3.46–434.76 U/ml, reportable range was 6.00–535.13 U/ml, and a suitable reference interval was 0.00–20.00 U/ml.
- High correlation (r=0.982) with the CanAg kit, no significant interference from common substances, and no cross-reactivity with other tumor markers were observed.
Conclusions:
- The new CA24-2 quantitative assay kit demonstrates robust detection performance on the TESMI F3999-Luminex200 system.
- The assay kit is accurate, precise, and reliable, showing good agreement with the CanAg kit.
- This new CA24-2 assay kit is suitable for clinical examination of CA24-2 in laboratory settings.
